Myeloproliferative Neoplasms | Specialty

Real-World Use of Ruxolitinib in Polycythemia Vera

March 17th 2021

Experts give real-world insight in using ruxolitinib in patients with polycythemia vera. 

FDA Issues Complete Response Letter for Ropeginterferon Alfa-2b for Polycythemia Vera

March 15th 2021

The FDA has issued a complete response letter regarding the biologics license application for ropeginterferon alfa-2b-njft for the treatment of patients with polycythemia vera.

Polycythemia Vera: An Update on Clinical Trials

March 10th 2021

Experts discuss clinical trial updates in polycythemia vera, including data from RESPONSE, RESPONSE-2, an international observational study of ruxolitinib, and REVEAL.

PV Progression and Guideline-Directed Management

March 10th 2021

Ruben A. Mesa, MD, highlights signs of disease progression and the utilization of guideline recommendations in the occurrence of a thrombotic event when treating polycythemia vera.

Interferon-Alpha Improves MFS and OS Over Standard Approaches in Polycythemia Vera

March 9th 2021

Interferon-alpha has been shown to significantly improve both myelofibrosis-free survival and overall survival over hydroxyurea and phlebotomy only in patients with polycythemia vera.

Approaches Abound for Managing Symptoms Associated With Myelofibrosis

March 4th 2021

Srdan Verstovsek, MD, PhD, shares recommendation updates for myelofibrosis treatment and emerging options under exploration to effectively manage disease-related symptoms.

Targeted DNA Sequencing Informs Posttransplant Relapse Rates in MDS

March 3rd 2021

Targeted DNA sequencing prior to transplant can be used to determine which patients with myelodysplastic syndrome are at high risk for posttransplant relapse and should forego reduced-intensity conditioning in lieu of myeloablative conditioning.

Therapeutic Considerations in Polycythemia Vera

March 3rd 2021

Key opinion leaders discuss treatment goals, considerations, and guideline recommendations for patients with low- or high-risk polycythemia vera.

Diagnosis and Evaluation in Polycythemia Vera

March 3rd 2021

Evaluating treatment, diagnostic criteria, and risk-assessment tools in polycythemia vera.

Novel Concepts to Improve Survival, Manage Associated Symptoms in Myelofibrosis

March 2nd 2021

Several novel therapeutics such as JAK inhibitors and luspatercept have been developed for the treatment of patients with myelofibrosis and its associated symptoms, paving the way for improved survival rates and new combination strategies over the last decade.

An Overview of Myeloproliferative Neoplasms

February 26th 2021

Srdan Verstovsek, MD, PhD, provides an overview of the similarities and differences between myeloproliferative neoplasms, including polycythemia vera, myelofibrosis, and essential thrombocythemia.

Individualizing Treatment Approaches in MPN

February 26th 2021

Experts provide insight on therapeutic approaches of myeloproliferative neoplasms, highlighting clinical trial data and disease characteristics of polycythemia vera, primary myelofibrosis, and essential thrombocythemia.

Ruxolitinib Delivered at Maximum Dose Peri-Transplant Proves Safe in Myelofibrosis

February 10th 2021

February 10, 2021 - The JAK 1/2 inhibitor ruxolitinib, when given at a maximum dose of 10 mg peri-transplant, has been shown to be safe and feasible in patients with myelofibrosis.

Fedratinib Approved in Europe for Newly Diagnosed and Previously Treated Myelofibrosis

February 9th 2021

February 9, 2021 - The European Commission has granted a full marketing authorization for fedratinib for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocytopenia myelofibrosis who have not received JAK inhibitors or who have received ruxolitinib.

JSP191 With Low-Dose Irradiation and Fludarabine Shows Promise in MRD+ AML/MDS

February 9th 2021

February 9, 2021 - JSP191 in combination with low-dose total body irradiation and fludarabine has demonstrated efficacy and tolerability in older patients with minimal residual disease–positive acute myeloid leukemia and myelodysplastic syndrome who are undergoing nonmyeloablative allogeneic hematopoietic cell transplantation.

Mesa and Gerds Talk Management Strategies and Emerging Agents in Myelofibrosis

February 4th 2021

Dr. Mesa and Dr. Gerds provide insight into the current utility of JAK inhibitors in myelofibrosis, unmet needs, and novel agents and combination strategies in the pipeline.

MPN Efforts Set Sights on Improved Survival and Symptom Burden

February 2nd 2021

Shella Saint Fleur-Lominy, MD, PhD, discusses the current landscape of MPNs and the importance of addressing disease burden and progression.

Imetelstat Has Disease-Modifying Activity in Relapsed/Refractory Myelofibrosis, as Shown by Effect on Telomerase Activity

January 19th 2021

January 19, 2021 - Imetelstat exhibited dose-dependent inhibition of the telomerase target, as evaluated by reductions in telomerase activity, human reverse transcriptase levels, and telomere length, in patients with relapsed/refractory myelofibrosis who were enrolled in the phase 2 IMbark trial.

Tamoxifen Reduces Mutation Allele Burden in MPN Subset Identified Via RNA Sequencing

January 18th 2021

January 18, 2021 - The phase 2 TAMARIN study exploring the activity of tamoxifen on driver variant allele frequency in patients with stable myeloproliferative neoplasms met its primary end point.

Rapid Readouts: Phase 2 Study of Navitoclax in High-Risk Myelofibrosis

January 15th 2021